AstraZeneca is also investing heavily in infrastructure, announcing up to $50 billion in US manufacturing and R&D investments through 2030, including a major drug-substance production facility in Virginia focused on next-generation metabolic medicines
Lopes FHA, Freitas MVC, de Bruin VMS, de Bruin PFC
J Biol Chem 267 , 2143221437 (1992)
Key benefits of CJC-1295 include: Sustained release of growth hormone Increased IGF-1 levels, which help with tissue repair, skin health, and lean muscle Support for fat loss, recovery, and performance Potential improvements in sleep and energy Side effects are typically minimal, with the most common being mild irritation at the injection site or short-term fatigue